These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 30087692)

  • 1. Identification of Mutation Regions on
    Xu M; Xiong H; Han Y; Li C; Mai S; Huang Z; Ai X; Guo Z; Zeng F; Guo Q
    Front Genet; 2018; 9():270. PubMed ID: 30087692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clustering of mutations in the 5' tertile of the NF1 gene in Slovakia patients with optic pathway glioma.
    Bolcekova A; Nemethova M; Zatkova A; Hlinkova K; Pozgayova S; Hlavata A; Kadasi L; Durovcikova D; Gerinec A; Husakova K; Pavlovicova Z; Holobrada M; Kovacs L; Ilencikova D
    Neoplasma; 2013; 60(6):655-65. PubMed ID: 23906300
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Optic Pathway Glioma in Neurofibromatosis Type 1: No Evidence of Genotype-Phenotype Correlations in A Large Independent Cohort.
    Melloni G; Eoli M; Cesaretti C; Bianchessi D; Ibba MC; Esposito S; Scuvera G; Morcaldi G; Micheli R; Piozzi E; Avignone S; Chiapparini L; Pantaleoni C; Natacci F; Finocchiaro G; Saletti V
    Cancers (Basel); 2019 Nov; 11(12):. PubMed ID: 31766501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
    Freret ME; Gutmann DH
    J Neurosci Res; 2019 Jan; 97(1):45-56. PubMed ID: 29704429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey.
    Sharafi P; Varan A; Ersoy-Evans S; Ayter S
    Childs Nerv Syst; 2024 Feb; 40(2):511-515. PubMed ID: 37401974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No correlation between NF1 mutation position and risk of optic pathway glioma in 77 unrelated NF1 patients.
    Hutter S; Piro RM; Waszak SM; Kehrer-Sawatzki H; Friedrich RE; Lassaletta A; Witt O; Korbel JO; Lichter P; Schuhmann MU; Pfister SM; Tabori U; Mautner VF; Jones DTW
    Hum Genet; 2016 May; 135(5):469-475. PubMed ID: 26969325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optic Pathway Glioma in Children with Neurofibromatosis Type 1: A Multidisciplinary Entity, Posing Dilemmas in Diagnosis and Management Multidisciplinary Management of Optic Pathway Glioma in Children with Neurofibromatosis Type 1.
    Lohkamp LN; Parkin P; Puran A; Bartels UK; Bouffet E; Tabori U; Rutka JT
    Front Surg; 2022; 9():886697. PubMed ID: 35592129
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
    Friedrich RE; Nuding MA
    Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low-Grade Glioma 2004 trial UK cohort.
    Falzon K; Drimtzias E; Picton S; Simmons I
    Br J Ophthalmol; 2018 Oct; 102(10):1367-1371. PubMed ID: 29343527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optic pathway glioma and the sex association in neurofibromatosis type 1: a single-center study.
    Henning AM; Handrup MM; Kjeldsen SM; Larsen DA; Ejerskov C
    Orphanet J Rare Dis; 2021 Nov; 16(1):489. PubMed ID: 34809690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NF1 mutation-driven neuronal hyperexcitability sets a threshold for tumorigenesis and therapeutic targeting of murine optic glioma.
    Anastasaki C; Chatterjee J; Koleske JP; Gao Y; Bozeman SL; Kernan CM; Marco Y Marquez LI; Chen JK; Kelly CE; Blair CJ; Dietzen DJ; Kesterson RA; Gutmann DH
    Neuro Oncol; 2024 Aug; 26(8):1496-1508. PubMed ID: 38607967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A molecular analysis of individuals with neurofibromatosis type 1 (NF1) and optic pathway gliomas (OPGs), and an assessment of genotype-phenotype correlations.
    Sharif S; Upadhyaya M; Ferner R; Majounie E; Shenton A; Baser M; Thakker N; Evans DG
    J Med Genet; 2011 Apr; 48(4):256-60. PubMed ID: 21278392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurofibromatosis Type 1-Associated Optic Pathway Gliomas: Current Challenges and Future Prospects.
    Tang Y; Gutmann DH
    Cancer Manag Res; 2023; 15():667-681. PubMed ID: 37465080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitative MRI demonstrates abnormalities of the third ventricle subventricular zone in neurofibromatosis type-1 and sporadic paediatric optic pathway glioma.
    Boonzaier NR; Hales PW; D'Arco F; Walters BC; Kaur R; Mankad K; Cooper J; Liasis A; Smith V; O'Hare P; Hargrave D; Clark CA
    Neuroimage Clin; 2020; 28():102447. PubMed ID: 33038669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optic Pathway Glioma in Type 1 Neurofibromatosis: Review of Its Pathogenesis, Diagnostic Assessment, and Treatment Recommendations.
    Cassina M; Frizziero L; Opocher E; Parrozzani R; Sorrentino U; Viscardi E; Miglionico G; Midena E; Clementi M; Trevisson E
    Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31739524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
    Kotch C; Avery R; Getz KD; Bouffet E; de Blank P; Listernick R; Gutmann DH; Bornhorst M; Campen C; Liu GT; Aplenc R; Li Y; Fisher MJ
    Neuro Oncol; 2022 Aug; 24(8):1377-1386. PubMed ID: 35018469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history of optic pathway gliomas in a cohort of unselected patients affected by Neurofibromatosis 1.
    Trevisson E; Cassina M; Opocher E; Vicenzi V; Lucchetta M; Parrozzani R; Miglionico G; Mardari R; Viscardi E; Midena E; Clementi M
    J Neurooncol; 2017 Sep; 134(2):279-287. PubMed ID: 28577031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
    Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
    JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness in patients with optic pathway gliomas.
    Hepokur M; Sarici AM
    Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1757-1765. PubMed ID: 29754292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology.
    Toonen JA; Solga AC; Ma Y; Gutmann DH
    J Exp Med; 2017 Jan; 214(1):17-25. PubMed ID: 27923908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.